Daniel Steiners

We have been keeping a close eye on emerging data that describe the implications of climate change on diseases in our research portfolio. An increasing pool of modeling studies indicate that changes are likely in the epidemiology of certain vector-borne (e.g., malaria and dengue) and water-borne (e.g., cryptosporidiosis diarrhea) diseases because of rising global temperatures. Specifically, evidence suggests these conditions could be exacerbated in regions where they are already endemic and could spread to new areas. There is also concern that the effects could more severely impact populations in low- and middle-income countries depending on the resiliency of civic and health infrastructures. For these reasons and more we have worked with the Financial Times to review state-of-the-art knowledge on this topic. Please learn more at the links below!

62

2 Kommentare

How do you sustain a medication in the long run? The answer is too simple: accessibility and affordability. 71.91 % of the interviewed patients prefer the daily intake of a tablet. Last year, we saw such great treatments coming to the forefront, speaking of which gene therapy takes the limelight. Recently, innovators have been looking for oral drugs for sickle-cell disease. Now my question is: Can pills be used to cure sickle-cell disease, and can they match gene therapy? The answer to this is subjective. Gene therapy, such as CRISPR-based treatments like Casgevy and Lyfgenia, has shown remarkable effectiveness. But it comes with a high cost, with prices ranging from $2 million to $3 million per treatment. On the other hand, oral drugs like GBT021601 offer greater accessibility and potential impact on a larger scale. Why? Because they are: ⤷ Easier to manufacture ⤷ More scalable ⤷ Can reach a broader population Gene therapy directly targets the genetic cause of the disease in reducing pain and potentially curing sickle cell disease. But in addition to high cost, they come with side effects such as hair loss and infertility. --------------- While pill-based treatments may not offer the same profound effects on acute symptoms as gene therapy, their greater accessibility makes them more impactful on a broader scale. In #healthcare, the focus should be on achieving greater good for the majority. So, let me know your thoughts on this emerging controversy. Gene therapy or Oral drugs? Or both? #Genetherapy #AccesbilityInHealthcare 

41

3 Kommentare

👉 𝐈𝐍𝐒𝐏𝐈𝐑𝐈𝐍𝐆: 𝐓𝐡𝐞 𝐛𝐞𝐬𝐭 𝐬𝐮𝐦𝐦𝐚𝐫𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐝𝐚𝐲 𝐨𝐟 𝐈𝐂𝐓 & 𝐇𝐞𝐚𝐥𝐭𝐡 𝐖𝐨𝐫𝐥𝐝 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 Thanks a lot 🙏🏻 to all speakers and workshop chairs from bringing together so much knowledge, drive & inspiration for the future health (in my home town 😃). What an exiting times to live in and to be able to drive the transformation to hybrid care. 🤜🤛 Livestream for day 2 to follow at: https://lnkd.in/eMJqXGeA #IWC24 #hybridcare #digitalpharmaceuticalcare #medicatieproces9

31

I observed the NICE Board earlier. If you’ve never been before, it’s definitely worth checking out. Lots of interesting discussions and it’s a real testament to the transparency of NICE! Key discussion points included: 💊Real world evidence (RWE) – there’s been an increase in the topics RWE has been used in, and the RWE framework has been a vital part in supporting this 💊Guidance output – In 23/24, fewer technology appraisals were published than expected (93 topics, 85% of anticipated). This was due to some topics taking longer than the standard timelines, so they will be publishing later 💊Prioritisation Board – this has existed in shadow form but will soon be fully operational. It combines several guidance topic prioritisation groups into one, which will help to ensure decisions are integrated across the whole of NICE. The NICE Board discussed the importance of the representation of various perspectives, including patient/public, and national organisations such as the Department of Health and Social Care (DHSC), NHS England, and their Welsh and Northern Irish counterparts. On national bodies, the NICE Board agreed there was a need to balance ensuring these important bodies have some oversight of NICE’s pipeline, with maintaining NICE’s autonomy and independence. There will be collaboration and information sharing but the decision-making power will remain with NICE 💊Timeliness – NICE has metrics which consider how closely technology appraisals guidance has published to its marketing authorisation. NICE are making good progress here but it’s still an area NICE are monitoring. Timeliness is impacted by whether the topic is optimal or divergent – an optimal topic is where all aspects of the topic have gone to plan, whereas a divergent topic is where there have been issues which have delayed the topic 💊NICE website – NICE are planning updates to help the usability of the website, which they hope will go live in May/June 💊Modular updates – a topic close to my heart, as I was responsible for developing this area in my previous role of Senior Technical Adviser at NICE! NICE plans to update future methods in a more modular way, as and when needed, rather than updating the entirety of the manual every few years. The group responsible for deciding which modules will be prioritised will include senior representation balanced with people with expert technical knowledge of processes and methods. The NICE Board will be involved in prioritisation when there is a potentially big change to methods proposed, such as change to modifiers. It was noted that external bodies such as DHSC would also need to be kept informed about the potential for development in areas such as modifiers. And The Board noted the importance of being clear when a new method/s become operational so that all stakeholders, including the NICE Appeal Panel, are clear which methods should be applied  💊Severity - NICE continue to monitor its use AXIS Healthcare Consulting Ltd

66

2 Kommentare

Interesting developments in the Pharma industry!

5

Be it in the Land of the Rising Sun or the Land of Opportunities, I saw yet again that colleagues at Boehringer Ingelheim are ONE in patient focus - in every plan and initiative. Over the past few weeks, I had the opportunity to visit colleagues and teams in the US and Japan. I am personally filled with so much learning and experiences that I am grateful to the colleagues that made these visits and meetings meaningful. My colleagues and I return enriched by the vibrant discussions, solution orientation and openness to feedback and sharing.     Of all the experiences, there is one that stands out – the power of direct exchange. At the root of every success story was a discussion and a thirst to learn, understand and continuously educate ourselves. That these discussions were centered around holistic care for patients from screening, diagnosis, treatment and prognosis / care was most heartening! In the US, I saw strong collaboration between teams and deep insight into patient perspectives, as they navigate complex and ever-changing healthcare environments. In Japan, I was humbled by the level of partnership, collaboration and commitment that colleagues brought to their work every day. Both teams, in their open and direct exchange are focusing on delivering healthcare accessibility and needs-based treatment. I believe that continuing with such direct exchange with help us bring together insights from across the world on clinical trials, research and public-private partnerships, thus enabling us to harness the power of science and innovation across borders, to deliver value for patients. #Cooperation #Partnerships #PatientCentricity #DirectExchange 

319

3 Kommentare

Thanks Handelsblatt for the great discussion on GLP-1 and sharing my perspective on the impact on life sciences companies. We are just starting a journey of disruption - but these innovation are what make our industry so exciting. https://lnkd.in/gi-Ue7Bi

49

🔬 Pharma Update 🔬 "Some of the topics from the last two weeks that caught my attention:" - Fresenius Group Sells majority of its rehabilitation business to a private equity firm, a strategic move to reduce debts as part of its corporate restructuring. - Novartis Acquires US-based nuclear medicine company, Mariana Oncology, for $1 billion, advancing its capabilities in innovative tumor treatments. - Bayer Achieves a significant legal victory concerning PCB liabilities from Monsanto, positively impacting its stock. - Novo Nordisk Nordisk: As the value of the diet injection market approaches $100 billion, supply struggles to meet the soaring demand, underscoring Novo Nordisk's market dominance. - Merck Gruppe Announces a €300 million investment in a new research center in Germany, set to house 550 employees by 2027, with Chancellor Scholz endorsing the initiative. - CureVac Plans to cut 10% of its workforce following setbacks in vaccine development and other corporate challenges. - Aenova Group Acquired by billionaire Kühne, highlighting the strategic shift towards pharmaceutical contract manufacturing. - Novartis Leadership: Welcomes a new CEO from Bristol Myers Squibb, as Jörg Reinhardt steps down after twelve years. - Boehringer Ingelheim Ingelheim: Commits €500 million to expand operations in China, targeting significant growth in the pharmaceutical sector. 📈 Stay tuned for more insights! #PharmaNews #HealthcareIndustry #Pharmaceuticals #manufacturing #training

5

Roche announced today that the European Commission has approved Alecensa® (alectinib) monotherapy, as adjuvant treatment following tumour resection for adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) at high risk of recurrence (Stage IB [≥4 cm]–IIIA NSCLC [7ᵗʰ edition UICC/AJCC]). Data from the Phase III ALINA trial, where Alecensa demonstrated an unprecedented 76% reduction in the risk of disease recurrence or death in people with resected ALK-positive NSCLC, supported the marketing authorisation application. “For the first time, people in Europe who have undergone surgical resection of ALK-positive NSCLC can be treated with an ALK inhibitor, which can significantly reduce the risk of disease recurrence or death,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This is a landmark approval for people who have historically faced a high risk of their cancer returning after surgery. We are now able to bring the transformational benefits of Alecensa to even more people with ALK-positive lung cancer.” “When it comes to early stage ALK-positive NSCLC, surgery is not always enough as there remains a high risk of recurrence that leaves patients concerned about what’s to come,” said Professor Fabrice Barlesi, thoracic oncologist, Université Paris-Saclay and chief executive officer of Gustave Roussy Institute . “The magnitude of disease-free survival benefit observed in the ALINA study was unprecedented and consistent across all disease stages. The use of early ALK testing will help to identify all patients that could benefit from this important new treatment option.” Alecensa is the preferred treatment option for patients with advanced ALK-positive NSCLC and has transformed outcomes for people with this disease. Approved in more than 100 countries as a first- and second-line treatment, more than 94,000 patients with advanced disease have been treated with Alecensa in clinical practice. Following its approval in the adjuvant treatment setting, Alecensa could for the first time play a pivotal role in ALK-positive resectable disease, where there is a significant unmet medical need. Today’s approval in Europe follows the April 2024 U.S. Food and Drug Administration (FDA) approval of Alecensa as adjuvant treatment following tumour resection for patients with ALK-positive NSCLC (tumours ≥ 4 cm or node positive), as detected by an FDA-approved test. Submissions to additional health authorities worldwide are ongoing to bring this much-needed new treatment option to as many patients as possible. #lungcancer #NSCLC #alectinib #Alecensa #Roche

379

2 Kommentare

#AI can help us deliver healthcare in a world with too few doctors, according to ZS CEO Pratap Khedkar and Principal Ahmed Albaiti. Find out the shifts the industry will need to make—and why the authors are optimistic about a future of healthcare abundance. https://lnkd.in/euCuqhsB

7

🚀 Boehringer Ingelheim's Ambitious Launch Plans: 25 New Drugs by 2030 💊 German pharmaceutical giant Boehringer Ingelheim is setting the stage for an exciting decade ahead, with plans to launch an impressive 25 new drugs by 2030. This ambitious roadmap showcases the company's commitment to innovation and its dedication to improving patient lives across various therapeutic areas. Notably, Boehringer Ingelheim is poised to make significant strides in the oncology space, with two new cancer drug launches slated for 2025. These upcoming releases will demonstrate the company's growing expertise in developing groundbreaking cancer treatments and its focus on addressing unmet medical needs. As the healthcare industry continues to evolve and face new challenges, Boehringer Ingelheim's robust pipeline and strategic launch plans position the company for sustained growth and impact. The next few years promise to be transformative not only for the drugmaker but also for the patients who stand to benefit from these innovative therapies. What are your thoughts on Boehringer Ingelheim's ambitious plans? How do you think these upcoming launches will shape the pharmaceutical landscape? Share your insights in the comments below! #BoehringerIngelheim #DrugDevelopment #Oncology #PharmaInnovation #HealthcareFuture

4

We cannot solve problems of today and tomorrow with solutions from yesterday. Especially not in health and care! I am looking forward to joining this year’s Geneva Digital Health Day as a keynote speaker on May 30. Introducing the Novartis Foundation’s population health initiative AI4HealthyCities, I’d like to inspire timely conversations about the much-needed, deep integration of AI in fundamental health decision making processes. Only by leveraging the power of advanced analytics and AI, we will be able to decipher what drives a population’s health outcomes at scale – and act on it accordingly. Will I see you there? More information: https://lnkd.in/ejDyfe9X #PopulationHealth #HealthData #HealthEquity

113

15 Kommentare

Transformation and turnarounds in pharma are complex. The industry presents unique challenges and opportunities. From a consultant’s standpoint, there are a few specific areas that need attention to be successful in a transformation: Stakeholder alignment - Ensure that everyone, from the C-suite to the factory floor, is on board with the transformation. This requires information, explanation, and top-to-bottom commitment. Define teams, process KPIs and governance and make sure everyone is aware how project will be run Make technology and data your strength. Leveraging technology and updating legacy systems will make any transformation easier and smoother. Financial discipline is paramount. This requires cutting costs where necessary and investing in areas that will deliver growth. Regulatory compliance at every stage is mandatory. This one seems straightforward but you don't want to do all this work only to discover you’ve run afoul of the law. Communicate while executing, you want to share success, be open about what is happening… the organization is not silly, they are all aware that some painful decision need to be taken, but in general they appreciate honesty and transparency. What other factors are important to a pharma transformation or turnaround? #PharmaTransformation #StakeholderAlignment #TechInPharma #FinancialDiscipline #RegulatoryCompliance

4

At Bayer, #leadership is completely rethought and practiced! In this video, our board member Heike Prinz explains what this means and the potential that lies in turning leaders from managers into visionaries, architects, catalysts and coaches. #VACC #DSO #TeamBayer

1

Rare diseases need our attention, not just on Rare Disease Day. Recently published research from SMA Europe and Roche benchmarks care for adults living with spinal muscular atrophy (SMA) across Europe. It provides a comprehensive analysis of the situation faced by a group that makes up 50% of the SMA population. The key takeaway? While innovations in care are changing lives, not enough is being done for adults with SMA, who still face significant challenges. The findings underscore the urgent need for a holistic approach to SMA care, one that supports individuals at all time points throughout their lifetime. Despite the need for improvements, there are clear examples of best practice care for adults with SMA being implemented by healthcare professionals, policy makers and patient groups around Europe, demonstrating encouraging opportunities for progress. For those looking to dive deeper into the findings, please visit https://lnkd.in/grkSNEin. It's time to push for improvements in care for all those affected by SMA. #SpinalMuscularAtrophy #SMA #RareDisease

217

4 Kommentare

Fresenius Kabi, a subsidiary of Fresenius SE, has announced the availability of Tyenne®, the first tocilizumab biosimilar in the U.S. This biosimilar, 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝗯𝘆 𝘁𝗵𝗲 𝗙𝗗𝗔 𝗳𝗼𝗿 𝗯𝗼𝘁𝗵 𝗶𝗻𝘁𝗿𝗮𝘃𝗲𝗻𝗼𝘂𝘀 𝗮𝗻𝗱 𝘀𝘂𝗯𝗰𝘂𝘁𝗮𝗻𝗲𝗼𝘂𝘀 𝘂𝘀𝗲, offers a more accessible and affordable treatment option for patients with chronic autoimmune diseases. Tyenne®'s launch contributes significantly to Fresenius' (Bio)Pharma platform, aligning with its #FutureFresenius strategy. 𝗧𝘆𝗲𝗻𝗻𝗲® 𝗺𝗮𝗿𝗸𝘀 𝗙𝗿𝗲𝘀𝗲𝗻𝗶𝘂𝘀' 𝘁𝗵𝗶𝗿𝗱 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗶𝗻 𝘁𝗵𝗲 𝗨.𝗦. 𝗮𝗻𝗱 𝘀𝗲𝗰𝗼𝗻𝗱 𝗶𝗻 𝗶𝘁𝘀 𝗶𝗺𝗺𝘂𝗻𝗼𝗹𝗼𝗴𝘆 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼. 𝗜𝘁 𝘁𝗿𝗲𝗮𝘁𝘀 𝘃𝗮𝗿𝗶𝗼𝘂𝘀 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝘀𝘂𝗰𝗵 𝗮𝘀 𝗿𝗵𝗲𝘂𝗺𝗮𝘁𝗼𝗶𝗱 𝗮𝗿𝘁𝗵𝗿𝗶𝘁𝗶𝘀 𝗮𝗻𝗱 𝘀𝘆𝘀𝘁𝗲𝗺𝗶𝗰 𝗷𝘂𝘃𝗲𝗻𝗶𝗹𝗲 𝗶𝗱𝗶𝗼𝗽𝗮𝘁𝗵𝗶𝗰 𝗮𝗿𝘁𝗵𝗿𝗶𝘁𝗶𝘀. Fresenius Kabi's CEO sees Tyenne® as a game-changer in the U.S. healthcare landscape, emphasizing their commitment to expanding patient access to advanced biopharmaceuticals. The company's support program aims to assist healthcare professionals and patients, ensuring broader access to treatment options. 𝗔𝗱𝗱𝗶𝘁𝗶𝗼𝗻𝗮𝗹𝗹𝘆, 𝗙𝗿𝗲𝘀𝗲𝗻𝗶𝘂𝘀 𝗞𝗮𝗯𝗶 𝗵𝗮𝘀 𝗮 𝗿𝗼𝗯𝘂𝘀𝘁 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 𝗼𝗳 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗮𝗻𝗱 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗶𝗻 𝗹𝗮𝘁𝗲-𝘀𝘁𝗮𝗴𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁, 𝗿𝗲𝗳𝗹𝗲𝗰𝘁𝗶𝗻𝗴 𝗶𝘁𝘀 𝗱𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻. Fresenius' overarching strategy, #FutureFresenius, focuses on becoming a leading therapy-focused company. #marketintelligence #competitiveintelligence #pharmaceutical #marketsmind #tocilizumab #freseniuskabi

19

1 Kommentar

Interesting article! According to article below the digital maturity hasn't progressed over the last year, despite many new offerings and clever software's. Reasons being: - Challenges for op's teams - Transitions taking longer time than anticipated - Financial burden Are you also finding it difficult to add new tech/processes currently? Why? #clinicaltrials #digitalization https://lnkd.in/dPhKXJpU

12

Patient centricity is critical to every aspect of the healthcare experience. Patients are better informed, more active and more determined than ever and successfully working in life sciences requires that the industry respond. https://lnkd.in/evBU8skn

17

Today is World Book Day. What a coincidence that I have the pleasure to launch a book myself today: “Leading in a Wicked World” Books have played a significant role in my life. Starting from great children’s books like “Alice in Wonderland” to inspiring books like Harari´s “Sapiens: A Brief History of Humankind”, McAffee´s "The Geek Way" or Gerste`s "Die Heilung der Welt" - or so many others . So I am proud that jointly with Sonja Wekema, we created one as well. This book is an essential read for those looking for success in today’s rapidly changing world. We offer you a wealth of knowledge and practical leadership strategies for leading in the Wicked World we live in, illustrated by real-world examples that bring these concepts to life. We explore: - The key trends shaping today’s business landscape and what leading really means in a Wicked World – a world of upheaval, growing complexity, digitization, and where old paradigms continue to crash. - How personal scripts and patterns affect leadership, plus how to shift your leadership style to better align with your organization’s needs. - A new framework that helps leaders make sense of organizations in a Wicked World. - Inspiration and suggestions of how you can dance with the Wicked World.   Creating that book was a wonderful journey in itself. Now we invite you to explore the Wicked World – and share your comments and feedback with us. Here is where the jounrey starts: https://a.co/d/geqLqWJ #WickedWorld #Leadership #Transformation

74

22 Kommentare